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EDITORIAL   
Atrial Fibrillation and Cognitive Impairment  
Antonis S. Manolis, MD 
Athens University School of Medicine, Athens, Greece  
ABSTRACT 
Growing evidence suggests that atrial fibrillation 
(AF), in addition to its known thromboembolic risk, is a 
risk factor for significant cognitive impairment via 
several pathways, further contributing to morbidity and 
mortality. Whether anticoagulation, rhythm control 
strategies and other interventions aiming at preventing 
thromboembolic events and ameliorating the clinical 
outcome of AF patients, may also have a beneficial effect 
on long-term cognitive function remains to be seen in 
future studies. (Rhythmos 2015;10(3):45-52)  
Key Words: atrial fibrillation; stroke; cognitive function; silent 
cerebral infarcts; brain hypoperfusion; dementia  
Abbreviations 
AF = atrial fibrillation; MRI = magnetic resonance imaging; 
TEE = transesophageal echocardiography; TTR = time to 
therapeutic ratio; VKA = vitamin K antagonists  
Introduction 
Atrial fibrillation (AF) is the commonest arrhythmia 
(1-2%) in the general population, while due to its age-
dependency its incidence may exceed 8-10% in the 
elderly, conferring considerable morbidity and mortality 
related to cardiovascular effects and thromboembolic 
complications, notably stroke.1, 2 Oral anticoagulants for 
prevention of strokes and antiarrhythmic drugs for rate 
and/or rhythm control are the cornerstone of 
contemporary management, whereas evolving 
transcatheter ablation techniques play an increasingly 
important role.3 
Mild cognitive impairment, initially defined as 
isolated memory deficit and later ascribed an expanded 
definition that includes different cognitive domains, can 
precede the development of dementia.4  Increasing 
evidence shows that AF is a risk factor for significant 
cognitive impairment in patients with and without a 
manifest stroke via a plethora of pathways (Table 1), 
further contributing to morbidity and mortality.5-8 Atrial 
fibrillation has also been associated with conversion of 
cognitive impairment to full dementia.4 Furthermore, 
previously undiagnosed AF should be suspected upon the 
emergence of cognitive decline associated with 
cryptogenic and/or silent strokes. Recent guidelines 
indicate that screening for AF should be undertaken with 
pulse taking and/or electrocardiography or rhythm 
monitoring in patients aged >65 years.9 The recently 
appreciated association of AF with cognitive decline 
should also lead to the concept of cognitive screening10 
and rhythm monitoring in the aforementioned populations 
(Fig. 1).5 Although dementia and AF are common 
comorbidities in stroke patients, AF appears to have a 
potential role in cognitive impairment prior to a first 
stroke. Whether anticoagulation, rhythm control 
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strategies and other interventions aiming at preventing 
thromboembolic events and ameliorating the clinical 
outcome of AF patients, may also have a beneficial effect 
on long-term cognitive function remains to be seen in 
future studies.   
Studies of Cognitive Impairment in Atrial Fibrillation 
According with a cross-sectional Swedish study based 
on a cohort of 952 community-living men, aged 69 to 75 
years, men with AF (n=44) had lower mean adjusted 
cognitive z scores than men without AF (P=0.0003).11  
The exclusion of stroke patients or adjustments for 24-
hour diastolic blood pressure and heart rate, diabetes, and 
ejection fraction did not change this relationship. Men 
with AF who were treated with digoxin (n=27) performed 
markedly better than those without treatment (n=9; 
P=0.0005). Thus, this study demonstrated an association 
between AF and low cognitive function independent of 
stroke, high blood pressure, and diabetes.  
A Framingham Study including 1011 men (mean age 
of 61 years) free of clinical stroke and dementia indicated 
that those with (n = 59) vs those without (n = 952) AF at 
8 months after the AF surveillance period exhibited 
significantly lower mean levels of cognitive 
performance.12 
In a cross-sectional evaluation of 122 stroke-free 
individuals with AF compared with 563 individuals aged 
37-84 years without AF, stroke-free individuals with AF 
performed significantly worse in tasks of learning and 
memory (P < 0.01) as well as attention and executive 
functions (P < 0.01).13  There was also a trend (P = 0.062) 
towards worse performance in learning and memory tasks 
in patients with chronic as compared with paroxysmal 
AF. Corresponding to the memory impairment, 
hippocampal volume on magnetic resonance imaging 
(MRI) was reduced in patients with AF. The authors 
concluded that even in the absence of manifest stroke, AF 
is a risk factor for cognitive impairment and hippocampal 
atrophy.  
A post-hoc analysis of 2 randomized controlled trials 
involving 31,506 patients (aged 66.5 years) and 
evaluating the efficacy of treatment with ramipril plus 
telmisartan (ONTARGET) or telmisartan alone 
(TRANSCEND) in reducing cardiovascular disease, 
indicated that AF was present at baseline in 1016 
participants (3.3%) and developed during follow-up 
(median 56 months) in an additional 2052 participants 
(6.5%).14 Atrial fibrillation was associated with an 
increased risk of cognitive decline (hazard ratio - HR 
1.14), new dementia (HR 1.30), loss of independence in 
performing activities of daily living (HR 1.35) and 
admission to long-term care facilities (HR 1.53), 
regardless of having a stroke or not, or receiving 
antihypertensive drugs. The authors concluded that 
cognitive and functional decline are consequences of AF, 
even in the absence of overt stroke.  
Among 270 individuals, 180 patients with AF (90 
paroxysmal and 90 persistent) and 90 controls, at least 1 
area of silent cerebral ischemia on MRI was present in 80 
patients (89%) with paroxysmal AF, 83 (92%) with 
persistent AF, and 41 (46%) controls (p < 0.01).15 The 
number of areas of silent cerebral ischemia per subject 
was higher in patients with persistent AF than in those 
with paroxysmal AF (41.1±28.0 vs 33.2 ± 22.8, p = 0.04). 
Cognitive performance was significantly worse in 
patients with persistent and paroxysmal AF than in 
controls.  
A recent prospective observational study evaluated the 
prevalence of prestroke cognitive impairment in 788 
stroke patients (69.5% ischemic strokes, 21.3% transient 
ischemic attacks, and 9.1% hemorrhagic strokes), and 
examined whether AF was associated with prestroke 
cognitive impairment.16 Prestroke cognitive impairment 
was detected in 96 (12.5 %) patients. Of these, 33 
patients (4.3 %) were demented before the actual stroke 
event. AF was independently associated with prestroke 
cognitive impairment. The authors concluded that 
patients with an acute stroke frequently show a history of 
cognitive impairment before the event; AF is 
independently associated with prestroke cognitive 
impairment.  
According to a longitudinal analysis in the 
Cardiovascular Health Study, a community-based study 
of 5,150 men and women aged >65 years, who did not 
have AF or a history of stroke at baseline, 552 (10.7%) 
developed incident AF during a mean follow-up of 7 
years.17  Cognitive function was tested with use of the 
Modified Mini-Mental State Examination (3MSE), which 
is a general screening tool assessing memory, orientation, 
calculation, and verbal fluency. Scores on the 3MSE 
range from zero (worst) to 100 (best) with a cutoff of <78 
points for dementia screening. Mean 3MSE scores 
declined faster after incident AF compared with no prior 
AF, e.g. the predicted 5-year decline in mean 3MSE score 
from age 80 to age 85 was 26.4 points for individuals 
without a history of AF, but was 210.3 points for those 
experiencing incident AF at age 80, a 5-year difference of 
23.9 points. The authors concluded that in the absence of 
prior stroke, people with incident AF are likely to reach 
thresholds of cognitive impairment or dementia at earlier 
ages than people with no history of AF.  
A recent Australian prospective substudy of a 
multicenter randomized trial of an AF-specific disease 
management intervention (the Standard versus Atrial 
Fibrillation spEcific managemenT studY; SAFETY) 
examined the incidence of mild cognitive impairment 
among 260 patients with chronic AF, aged 72±11 years 
(53% men, mean CHA2DS2-VASc score 4±2) and 
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sought to identify predictors of this cognitive 
dysfunction.18  A total of 169 patients (65%) were found 
to have mild cognitive impairment at baseline with 
multiple deficits in cognitive domains, most notably in 
executive functioning, visuospatial abilities and short-
term memory. Predictors of impaired cognition were 
lower education level (odds ratio - OR 5-6), higher 
CHA2DS2-VASc score (OR 1.46) and prescribed 
digoxin (OR 2.19). The authors concluded that mild 
cognitive impairment is highly prevalent among older 
high-risk patients hospitalized with AF.  
Even in patients with heart failure having their own 
reasons for cognitive decline, the occurrence of AF 
further exacerbates cognitive dysfunction. According to a 
recent study, among 187 patients with heart failure,19  
those with AF (32.1%) exhibited worse global cognition, 
memory, and cerebral blood flow velocity of the middle 
cerebral artery relative to patients without AF, above and 
beyond the effects that could be ascribed to heart failure 
severity and other demographic and medical factors. 
Partial correlations controlling for possible confounds 
showed that decreased blood flow velocity of the middle 
cerebral artery predicted worse cognition in multiple 
domains in the overall sample (r = 0.13 to 0.15, P < 0.05) 
and in the subgroup of heart failure patients with AF (r = 
0.26 to r = 0.28, P < 0.05), but not among heart failure 
patients without AF. The authors concluded that AF 
exacerbates cognitive deficits in heart failure, possibly 
through its association with decreased cerebral perfusion.  
A metaanalysis of 14 studies including 46,637 
patients, aged 71.7 years, showed that AF was associated 
with a significant increase in dementia overall (odds 
ratio-OR 2.0, p<0.0001), albeit with substantial 
heterogeneity.6 When stratified by participants, the 
association was significant (with little heterogeneity) in 
studies focusing solely on patients with stroke (7 studies, 
OR 2.4, p < 0.001), and of borderline significance (with 
substantial heterogeneity) for studies in broader 
populations (7 studies, OR 1.6, p=0.05). For conversion 
of mild cognitive impairment to dementia, one study 
showed a significant association with AF (OR 4.6). The 
authors concluded that there is consistent evidence 
supporting an association between AF and increased 
incidence of dementia in patients with stroke, but there 
remains considerable uncertainty about any link in the 
broader population.  
According to another metaanalysis of 8 studies with 
77,668 elderly patients, aged 61-84 years, with normal 
cognitive function at baseline, of whom 11,700 (15%) 
had AF, 4773 of 73,321 (6.5%) patients developed 
dementia at a mean follow-up of 7.7 ± 9.1 years.20  At 
pooled analysis adjusted for baseline confounders and 
covariates, AF was independently associated with 
increased risk of incident dementia (HR = 1.42, P <.001). 
The authors concluded that AF is independently 
associated with increased risk of dementia.  
In a recent review of studies comparing the incidence 
of cognitive impairment and/or dementia in patients 
with/without AF, 8 out of 11 studies (3 cross-sectional, 2 
case-control and 3 prospective cohorts) reported an 
association between cognitive decline and AF, but the 
risk varied.7  Among cross-sectional studies, patients with 
AF had a 1.7 to 3.3 greater risk of cognitive impairment, 
and a 2.3-fold increased risk of dementia, compared to 
patients in sinus rhythm.  
According with another meta-analysis of 21, albeit 
heterogeneous, studies, AF was significantly associated 
with a higher risk of cognitive impairment independent of 
stroke history (relative risk - RR =1.34), in patients with 
first or recurrent stroke (RR =2.7) and in a broader 
population of patients with or without a history of stroke 
(RR =1.4).21  Limiting the analysis to prospective studies 
yielded similar results (RR =1.36). Restricting the 
analysis to studies of dementia eliminated the significant 
heterogeneity (P value = 0.137) but did not alter the 
pooled estimate substantially (RR = 1.38). The authors 
concluded that evidence suggests that AF is associated 
with a higher risk of cognitive impairment and dementia, 
with or without a history of clinical stroke.  
One should also keep in mind some conflicting 
results. According with prospective 9-year follow-up 
population-based study in Finland, among 553 subjects 
(92% of the total population) aged >85 years, AF was 
significantly associated with stroke at baseline; (32% vs 
16.7%; P<0.001).22  Dementia at baseline was 
significantly associated with age, clinical stroke, and the 
presence of apolipoprotein E epsilon4 allele, but not with 
sex, education, or vascular risk factors. The authors 
concluded that AF is a significant and preventable risk 
factor for stroke but not for dementia in the very old. 
Similarly in a prospective longitudinal cohort study of 
362 men and women aged >60,23  there were no clinically 
important differences in cognitive function between 
baseline and follow-up at 1 and 3 years, between 174 AF 
cases and 188 controls in sinus rhythm, nor between 
subgroups on aspirin, warfarin or neither. 
However, accumulating data linking AF to not just 
mild cognitive impairment but to more advanced 
cognitive dysfunction (dementia) remain worrisome. A 
large cohort study indicated that among 37,025 
individuals from the Intermountain Heart Collaborative 
Study database (mean age 61+18 years),24 a total of 
10,161 (27%) developed AF and 1,535 (4.1%) developed 
dementia (179 vascular dementia, 321 senile dementia, 
347 Alzheimer’s, 688 non-specified) during a 5-year 
follow-up. Patients with dementia were older with higher 
rates of hypertension, coronary artery disease, renal 
failure, heart failure, and prior strokes. In age-based 
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analysis, AF independently was associated with all 
dementia types, with the highest risk in the younger 
group (<70). More importantly, in patients with dementia, 
AF was associated with a marked increased risk of 
mortality (hazard ratio ~ 1.4; P <0.0001).  
Etiology 
 A plethora of etiologies of cognitive impairment and 
dementia have been implicated in a variety of clinical 
conditions, among which vascular contributions 
predominate,25  but non-vascular causes are also 
important. Unfortunately, a 5-10% prevalence of 
dementia in affluent countries has been recognized in 
people >65 years of age.25 Even more importantly, in 
2002, an estimated 5.4 million people (22.2%) in the 
United States aged >71 years had cognitive impairment 
without dementia,26  while both ends of the spectrum are 
associated with excess mortality.8  The most important 
cerebrovascular pathology that contributes to cognitive 
impairment is cerebral infarcts and AF is a common 
source and cause of cerebral thrombo-embolism. 
However, cognitive decline has also been noted even in 
the absence of a clinically manifest stroke.  
Silent brain infarction is often found in patients with 
AF and has been proposed as possibly implicated in 
cognitive decline (Table 1). A group of 103 
neurologically asymptomatic patients (76 men, aged 63 ± 
10 years) with nonvalvular AF were screened for silent 
brain infarction with MRI and also underwent trans-
esophageal echocardiography (TEE) before transcatheter 
AF ablation (76 men; mean age 63 ± 10 years).27  A total 
of 31 (30%) patients showed silent brain infarction on 
brain MRI. Most lesions were multiple (61%) and small 
(<15 mm) in diameter (84%). Patients with silent brain 
infarction had a higher prevalence of left atrial 
abnormalities (45% vs 14%; P < .001) and complex aortic 
arch plaques (45% vs 7%; P < 0.001) compared with 
those without silent brain infarction. In multivariate 
analysis, left atrial abnormalities (odds ratio 4.13; P = 
0.014) and complex aortic arch plaques (odds ratio 4.82; 
P = 0.024) were independent predictors of silent brain 
infarction, suggesting that microembolization of small 
thrombi derived from the fibrillating left atrium or 
advanced aortic atherosclerotic lesions may be important 
causes of silent brain infarction in patients with 
nonvalvular AF.  
The prevalence of silent cerebral infarctions and their 
association with AF was estimated in a systematic review 
and meta-analysis of 11 studies including 5317 patients 
(aged 50 to 83.6 years) with AF and no clinical history of 
stroke or prosthetic valves.28 When computed 
tomography and MRI studies were combined, AF was 
associated with silent cerebral infarctions (odds ratio - 
OR, 2.62). This association was independent of AF type 
(paroxysmal vs persistent). The overall prevalence of 
silent cerebral infarction lesions, reported in 17 studies, 
among patients with AF was 40% on MRI and 22% on 
computed tomography. The authors concluded that AF is 
associated with more than a 2-fold increase in the odds 
for silent cerebral infarctions. 
The association of incident AF with cognitive decline 
was examined in stroke-free individuals, stratified by 
subclinical cerebral infarcts on brain MRI scans in the 
Atherosclerosis Risk in Communities (ARIC) Study.29  
During follow-up, there were 48 incident AF events 
among 935 stroke-free individuals (aged 61.5±4.3 years; 
62% women; 51% black). Incident AF was associated 
with greater annual average rate of cognitive decline 
tested by digit symbol substitution (-0.77; P=0.054) and 
word fluency (-0.80; P=0.048). Among participants 
without subclinical cerebral infarcts on brain MRI scans, 
incident AF was not associated with cognitive decline. 
The authors concluded that the association of incident AF 
with cognitive decline in stroke-free individuals can be 
explained by the presence or development of subclinical 
cerebral infarcts, raising the possibility that 
anticoagulation might prevent cognitive decline in AF.  
The possibility of exposure to chronic microembolism 
or microbleeds resulting in repetitive cerebral injury that 
is manifest by cognitive decline, has been suggested by a 
study examining the association of low percentage of 
time in the therapeutic range (TTR) to higher risk for 
dementia due to under- or over-anticoagulation. 
Dementia was diagnosed in 109 patients (4.2%) (senile: 
37 or 1.4%; vascular: 8 or 0.3%; Alzheimer: 64 or 2.5%) 
among 2605 AF patients (age 73.7 ± 10.8 years, 54% 
male) anti-coagulated with warfarin.30  The percent TTR 
averaged 63.1 ± 21.3, with percent INR <2.0: 25.6% ± 
17.9% and percent INR >3.0: 16.2% ± 13.6%. After 
adjustment, decreasing categories of percent TTR were 
associated with increased dementia risk (vs >75%): 
<25%: hazard ratio - HR 5.34, P < 0.0001; 26%-50%: HR 
4.10, P < 0.0001; and 51%-75%: HR = 2.57, P=0.001. 
The authors concluded that quality of anticoagulation 
management represented as percent TTR among AF 
patients without dementia was associated with dementia 
incidence.  
Thus, it is apparent that AF produces cognitive decline 
independent of stroke, suggesting additional effects of AF 
on the brain. In a cross-sectional analysis of 4251 non-
demented participants (mean age, 76 ± 5 years) in the 
population-based AGES-Reykjavik Study, 330 
participants had AF.31  Participants with AF had lower 
total brain volume on MRI compared with those without 
AF (P<0.001). The association was stronger with 
persistent/permanent than paroxysmal AF and with 
increased time from the first diagnosis of the disease. Of 
the brain tissue volumes, AF was associated with lower 
volume of gray and white matter hyperintensities 
49 
 
(P<0.001 and P = 0.008, respectively), but not of white 
matter hyperintensities (P = 0.49). Participants with AF 
scored lower on tests of memory. The authors concluded 
that AF is associated with smaller brain volume, and the 
association is stronger with increasing burden of the 
arrhythmia. These findings suggest that AF has a 
cumulative negative effect on the brain independent of 
cerebral infarcts. The difference in total brain volume 
between individuals with and without AF equals a year 
and a half of normal loss of brain volume. In their 
discussion the authors consider the possible explanatory 
mechanisms for their findings. The association between 
AF and brain atrophy and lower performance on memory 
tests could be attributed to increased comorbidity and 
cerebral infarcts in the AF population. AF causes 
multiple microembolisms and microinfarcts to the brain 
and subsequent atrophy. Additionally, cerebral 
hypoperfusion, attributable to beat-to-beat variation in 
stroke volume, also may play a part. Patients with 
persistent/permanent AF may have more cerebral 
hypoperfusion than those with only paroxysmal AF, 
explaining the finding of greater brain atrophy 
encountered in patients with persistent/permanent A.  
The hypotheses that hemostatic function is altered in 
subjects with AF who develop dementia, and that long-
term warfarin anticoagulation is protective against this 
complication were tested in an observational cohort study 
of 218 AF patients, of whom 145 (66%) were prescribed 
warfarin.32  Forty-nine (22%) met criteria for dementia 
after 3 years’ follow-up. D-dimer, prothrombin fragment 
1+2 and thrombin-antithrombin complexes levels were 
higher in AF subjects with dementia compared with those 
without (P = 0.003-0.008). These associations became of 
borderline statistical significance following adjustment 
for age. Logistic regression showed a trend towards 
warfarin use being independently associated with reduced 
prevalence of dementia (odds ratio 0.52, P = 0.08). The 
authors concluded that there is increased thrombin 
generation and fibrin turnover in subjects with AF and 
dementia compared with those without dementia. Long-
term warfarin use may be protective against the 
development of dementia in subjects with AF.  
The role of ventricular rate response on the incidence 
of dementia in elderly subjects with cognitive impairment 
and AF was examined in 358 cognitively impaired 
elderly subjects with and without AF, stratified in 
low/high (<50/>90) and moderate (>50/<90 bpm) 
ventricular rate response.33  Over 10 years, among these 
cognitively impaired subjects, 135 (37.7%) progressed to 
dementia, 33 in the presence (75%) and 102 (32.5%) in 
the absence of AF (p < 0.001). Multivariate analysis 
showed that AF was a strong predictor of dementia 
(hazard ratio - HR = 4.10; p < 0.001). Importantly, 
low/high ventricular rate response (<50/>90 bpm) was 
predictive of dementia in the presence (HR = 7.70, p = 
0.03) but not in the absence (HR = 1.85; p = 0.152) of 
AF. The authors concluded that AF predicts dementia in 
elderly subjects with cognitive impairment, and 
ventricular rate response seems to play a key role in the 
incidence of dementia in cognitively impaired elderly 
subjects with AF.   
Table 1. Mechanisms and Factors Implicated in 
Cognitive Impairment Associated With Nonvalvular 
Atrial Fibrillation (AF)   
● Silent (subclinical) brain infarction due to 
microembolization of small thrombi emanating from the 
fibrillating left atrium in under-anticoagulated patients or 
from advanced aortic atherosclerotic lesions or  
● silent cerebral microbleeds in over-anticoagulated 
patients   
● loss of brain volume (brain atrophy) / lower volume of 
gray and white matter attributed to increased comorbidity 
and cerebral micro-infarcts or microembolisms with 
subsequent brain atrophy in the AF population  
● cerebral hypoperfusion, attributable to beat-to-beat 
variation in stroke volume. Patients with 
persistent/permanent AF may have more cerebral 
hypoperfusion than those with only paroxysmal AF, 
explaining the finding of greater brain atrophy 
encountered in patients with persistent-permanent AF / 
low or high ventricular rate response (<50/>90 bpm) is 
predictive of dementia in the presence but not in the 
absence of AF.  
● altered hemostatic function in patients with AF who 
develop dementia / higher D-dimer, prothrombin 
fragment 1+2 and thrombin-antithrombin complexes 
levels / increased thrombin generation and fibrin turnover 
in individuals with AF and dementia compared with those 
without dementia   
● ? vitamin K deficiency in patients on vitamin K 
antagonists contributing to cognitive dysfunction, due to 
the potential role of vitamin K in brain physiology and a 
suggestion that its deficiency may induce cognitive 
decline   
● systemic inflammatory mechanisms as indicated by 
increased inflammatory markers correlating with 
neurocognitive functions and loss of volume    
Experimental data indicate that vascular oxidative 
stress and inflammation are key pathogenic factors in 
neurovascular dysfunction,25  and there is evidence that 
AF is associated with activated inflammatory 
mechanisms (reflected by an increase in various 
inflammatory markers), linked to the prothrombotic state 
of AF.34  Finally, there is information that vitamin K is an 
important nutritional factor of cognitive health during 
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aging and animal data suggest that deficient vitamin K is 
a potential mechanism of cognitive impairment,35  as 
lifetime consumption of a low-vitamin K diet is 
associated with higher levels of ceramides in the 
hippocampus, a key brain region in spatial memory and 
navigation; importantly, several studies have reported 
elevated levels of ceramides in neurodegenerative disease 
such as Alzheimer’s disease. This information has raised 
concerns about the role of vitamin K antagonists in 
patients with AF and cognitive impairment, which 
contradicts the protective role of anticoagulants in 
thrombo-embolic complications and their presumed 
benefit in cognition that these agents are expected to 
confer in AF patients.   
Interventions 
Firstly, according to the AFFIRM functional status 
substudy, cognitive function was similar in rate-control 
and rhythm-control strategies.36  Secondly, although one 
would have expected that oral anticoagulants would 
confer a protective effect in AF patients from cognitive 
decline, the data remain inconclusive.32,37According to a 
randomized controlled trial, the BAFTA study, there is no 
evidence that anticoagulation confers clinically important 
protection over aspirin against cognitive decline in AF in 
the first 33 months of treatment other than that provided 
by preventing clinical stroke.37Indeed, among 973 
patients with AF aged ≥75 years assigned to warfarin 
(n=488) or low-dose aspirin (n=485), there was no 
difference in cognitive function between the 2 groups at 9 
or 21 months. At 33-month follow-up, there was a non-
significant difference of 0.56 on adjusted analysis in 
favor of warfarin that decreased to 0.49 after multiple 
imputation.  
A concern has been raised whether vitamin K 
antagonists (VKAs) may further contribute to cognitive 
dysfunction, due to the potential role of vitamin K in 
brain physiology, as already mentioned, and a suggestion 
that its deficiency may induce cognitive decline. A 
geriatric study comprising 267 older patients (aged 83.4 ± 
8.1 years; 57% female) indicated that compared with 
participants without cognitive impairment (n = 70), those 
with compromised cognition used more frequently VKAs 
(p =0.038).38  The risk of cognitive impairment was 15% 
higher with VKAs; using VKAs was independently 
associated with cognitive impairment (adjusted odds ratio 
= 17.4, p = 0.028). Taking into consideration this latter 
caveat, it is bestowed upon future comparative trials to 
deduce any differential effect of the newer non-vitamin K 
anticoagulants on cognition in patients with AF.  
A small group of 34 older patients with AF were 
treated with intensive lipid-lowering therapy with 
atorvastatin 40 mg and ezetimibe 10 mg (n=17), or 
placebo (n=17).39  Significant reductions in inflammatory 
markers were recorded in the treatment group compared 
to placebo. Reduction in plasma concentration of 
inflammatory markers correlated significantly with 
improvement in the neurocognitive functions memory 
and speed. Loss of volume in amygdala and 
hippocampus, as determined by MRI, was reduced in the 
treatment arm, statistically significant for left amygdala. 
The authors concluded that therapy with atorvastatin and 
ezetimibe can modify the decline of neurocognitive 
function, and the loss of volume in certain cerebral areas 
in older patients with AF.  
The risk of non-vascular dementia was compared 
between statin (n = 51,253 AF patients aged ≥60 years 
who had received statin treatment) and control groups (n 
= 205,012 age- and gender-matched AF patients not on 
statin) (data from the National Health Insurance Research 
Database of Taiwan).40 During follow-up, 17,201 patients 
experienced non-vascular dementia. The annual incidence 
of non-vascular dementia was lower in the statin group 
than in the control group (1.89% vs. 2.20%; p<0.001). 
Statin use exhibited a protective effect on the occurrence 
of non-vascular dementia, with an adjusted hazard ratio 
(HR) of 0.832. Among statin types, the use of 
rosuvastatin was associated with the largest risk reduction 
(adjusted HR=0.661). The authors concluded that statin 
use conferred a lower risk of non-vascular dementia in 
AF. Use of more potent statin and longer exposure 
duration may be associated with greater benefits.  
According with an observational study, those 
(n=4,212) who underwent radiofrequency ablation 
therapy for AF, which currently offers a best available 
rhythm control strategy for AF, had significantly lower 
risk for dementia than age/gender matched AF patients 
who did not have an ablation (n=16,848) and similar to 
the risk of age/gender matched controls without AF 
(n=16,848).41  Of the 37,908 patients, aged 65 ± 13 years, 
5,667 (14.9%) died, 1,296 (3.4%) had a stroke, and 1,096 
(2.9%) were hospitalized for heart failure over >3 years 
of follow-up. AF ablation patients had a lower risk of 
death and stroke in comparison to AF patients without 
ablation. Alzheimer's dementia occurred in 0.2% of the 
AF ablation patients compared to 0.9% of the AF no 
ablation patients and 0.5% of the no AF patients (P < 
0.0001). Other forms of dementia were also reduced 
significantly in those treated with ablation. Compared to 
patients with no AF, AF ablation patients had similar 
long-term rates of death, dementia, and stroke. The 
authors concluded that AF ablation patients have a 
significantly lower risk of death, stroke, and dementia in 
comparison to AF patients without ablation.   
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FIGURE 1. A suggested algorithm for screening for 
atrial fibrillation (AF) and/or mild cognitive impairment 
(MCI). ECG = electrocardiogram; LAA = left atrial 
appendage; MRI = magnetic resonance imaging; NOACs = 
non-vitamin K oral anticoagulants; PVI = pulmonary vein 
isolation (via radiofrequency or cryoballoon ablation); VKA = 
vitamin K antagonists; VR = ventricular rate   
* Rapid Cognitive Screen (RCS) for Mild Cognitive 
Impairment (MCI) / (0-5 = dementia; 6-7 = MCI; 8-10 = 
normal):44 
● Recall 5 objects (Apple, Pen, Tie, House, Car) / Recall 
objects after clock drawing (5 points) 
● Clock Drawing (Draw with time at 10 minutes to 11 o’clock) 
(4 points) 
● Insight: Jill was a very successful stockbroker. She made a 
lot of money on the stock market. She then met Jack, a 
devastatingly handsome man. She married him and had 3 
children. They lived in Chicago. She then stopped work and 
stayed at home to bring up her children. When they were 
teenagers, she went back to work. She and Jack lived happily 
ever after. What country did they live in? (1 point)   
** Thromboembolic / hemorrhagic risk commensurate with 
CHA2DS2-VASc / HAS-BLED scores, respectively    
The above results contrast with reports indicating that 
the ablation procedure itself may be associated with 
microinfarcts affecting patients’ memory.42, 43  According 
to a small study, among 21 AF patients undergoing 
ablation, 3 (14%) developed new ischemic lesions 
detected on MRI shortly after intervention (clinically 
symptomatic in 1 and clinically silent in 2).42In contrast 
to the control group (non-AF controls, n= 23) and in 
covariance of baseline performance, the ablation group 
showed worse neuropsychological outcome in verbal 
memory at 3 months post-procedurally. The authors 
concluded that adverse neuropsychological changes after 
AF ablation may represent cerebral complications of this 
procedure. In a larger study comprising 90 patients with 
AF undergoing ablation, post-operative neurocognitive 
dysfunction occurred in 13% - 20% at the 3-month 
follow-up compared with 0% in the non-ablation AF 
group.43  No studies comparing different modes of AF 
ablation (e.g. radiofrequency versus cryo-balloon 
ablation) and their effect on neurocognitive function have 
been conducted to date.  
Finally, other modes of AF management, such as 
surgical or percutaneous closure of left atrial appendage, 
have not been explored whether they have an effect on 
cognition. However, the problem of cognitive impairment 
appears to be real and of utmost importance to consider in 
the AF patient population, and recommendations have 
been put forth advocating that all patients with AF be 
screened for cognitive decline and all patients with 
cognitive decline be screened for AF.5  
Conclusion 
There appears to be convincing evidence accumulated 
todate suggesting that AF, in addition to its known 
thromboembolic risk, is a risk factor for a whole 
spectrum of cognitive impairment by a variety of 
mechanisms, further contributing to morbidity and 
mortality. Screening for both conditions is strongly 
advisable (Figure 1).5, 10  Preliminary evidence indicates 
that anticoagulation, rhythm and rate control strategies 
may have a significant protective action, particularly at 
the early stages of the disease when mild cognitive 
impairment may still be a treatable condition,44  although 
future randomized control studies are needed to further 
establish such claim.   
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